Trigger Alert: 4M Therapeutics Taps Sci-Advisor to Ignite Your Pipeline

🚀 Battle Card: 4M Therapeutics Inc.

• Edward Scolnick, M.D., Senior Scientific Advisor

• Bringing on a neuroscience legend fast-tracks biomarker validation and clinical credibility for bipolar disorder programs → Source

• This 4M Therapeutics Inc. sales trigger sends a clear signal: they’re doubling down on R&D differentiation.

• Limited efficacy and safety profiles in existing bipolar therapies

• Lack of validated, human-relevant biomarkers de-risking IND submissions

• Primary: Human neuronal cell–based screening platform → cut lead optimization time by 30%

• Expansion: Clinical biomarker qualification services → accelerate Phase I readiness

• HQ: Skillman, NJ

• Employees: ≈ 50

• Rev: ≈ $5 M

• Website: [4mtx.net](https://www.4mtx.net/)

🤼 Competitive Intel

• Recursion Pharmaceuticals — Phenotypic screening / AI-driven drug discovery
• Unique edge: Vast proprietary image dataset
• Evaluated by Sr. Sci. Advisor for automation & scaling

• Charles River Laboratories — Preclinical CRO services
• Unique edge: End-to-end GLP-compliant studies
• Evaluated by Dir. R&D for regulatory breadth

• Evotec — Integrated drug discovery partnerships
• Unique edge: Target-to-clinic modular platform
• Evaluated by COO for flexible collaboration

• Quanterix — Ultra-sensitive digital biomarker assays
• Unique edge: Single-molecule detection
• Evaluated by Head of Bioanalytics for precision readouts

✅ Do-Now Checklist

Next Step

🧠 Copy My Prompt for Personalized Cold Outreach

────────────────────────────
✏️ YOUR COMPANY
────────────────────────────
OUR_COMPANY   = ❑     ❑
OFFER_BRIEF   = ❑Human neuronal cell–based screening platform❑
PROOF_METRIC  = ❑cut lead optimization time by 30%❑
CTA_STYLE     = ❑quick_call❑
TONE          = ❑punchy❑

────────────────────────────
📌 TARGET COMPANY
────────────────────────────
NAME        = Edward
COMPANY     = 4M Therapeutics Inc.
DEPT        = R&D ≈
SIZE        = ≈ 50
BOTTLENECK  = ≈ limited validated biomarkers slows program advancement
EVENT       = Appointment of Industry Veteran Edward Scolnick, M.D., as Senior Scientific Advisor
DETAIL      = Appointment of Industry Veteran Edward Scolnick, M.D., as Senior Scientific Advisor
PAIN        = limited efficacy and safety profiles in bipolar therapies
SRC         = http://cts.businesswire.com/ct/CT?id=ftfLlWd9aZbF2NXfwppam3Bd664=&newsLang=en&newsId=20250925580935&div=41152219
SIM_CO      = Recursion Pharmaceuticals
WIN_METRIC  = cut lead optimization time by 30%
NEXT_SIZE   = ≈ 100
EMP_EST     = ≈ 50
REV_EST     = ≈ $5 M

────────────────────────
TASK FOR CHATGPT
────────────────────────
Role: “NewsletterForLeads SDR-Assist”.
Validate any ≈ guesses via SRC.

EMAIL  (keep breaks):
Subject: ≈50-person R&D

Edward—noticed your R&D team is ≈ 50.

That’s when ≈ limited validated biomarkers slows program advancement slows growth.

We helped Recursion Pharmaceuticals fix this with Human neuronal cell–based screening platform.

Result: cut lead optimization time by 30%.  
Quick call?

PS—next bottleneck hits ≈ 100.

DM ≤45 words, TONE:
Saw your post about Appointment of Industry Veteran Edward Scolnick, M.D., as Senior Scientific Advisor — limited efficacy and safety profiles in bipolar therapies.  
Human neuronal cell–based screening platform. cut lead optimization time by 30%. Quick chat?